Pharmaceutical Technology

APRIL 22, 2024

GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

98

98

European Pharmaceutical Review

MARCH 11, 2024

Since the HIV epidemic began in the early 1980s, more than 85 million people have been diagnosed worldwide and about 40 million have died as a result of complications from the virus. 1 Now, four decades later, 39 million people around the world are living with HIV, primarily due to advances in treatment.

Immunity 95

Immunity Immunization Clinical Pharmacology Drug Development 95

European Pharmaceutical Review

MAY 7, 2024

These treatments are indicated for the prevention of sexually transmitted HIV-1 infection — pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35kg with a higher infection risk, MHRA confirmed.

57

57

STAT

DECEMBER 20, 2022

Beginning in 2018 and through 2021, CytoDyn and its former CEO Nadir Pourhassan told investors repeatedly that a clinical trial had successfully demonstrated the effectiveness of an experimental treatment for HIV, and that a completed marketing application had been submitted to the U.S. Food and Drug Administration.

242

242

STAT

JUNE 28, 2023

The letter did not identify any issues with clinical efficacy or safety, trial design, labeling, or drug substance manufacturing, and no additional clinical data or study have been requested. A year after two major drugmakers sued a wholesaler for its alleged role in distributing counterfeit HIV pills, the U.S.

Labelling 230

Labelling 230

Pharmafile

MARCH 7, 2024

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 clinical study assessing the combination of islatravir and lenacapavir for viral suppression in HIV treatment.

59

59

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccines 145

Vaccines Immunity Immunization 145

Express Pharma

APRIL 7, 2023

Emcure Pharmaceuticals has been felicitated for its contributions to HIV/AIDS research and development at the HIV Congress 2023, organised by the HIV Welfare Society. The Merit Award acknowledges the firm’s contribution to the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.

98

98

Putting Patients First Blog

MARCH 11, 2024

National Women and Girls HIV/AIDS Awareness Day March 11, 2024 By: Lillian Witting, MPH, CAPM, Senior Coordinator of Research and Programs March 10 marks National Women and Girls HIV/AIDS Awareness Day during Women’s History Month, implemented by the Health and Human Services’ Office on Women’s Health. million people in the U.S.

Immunity 59

Immunity Immunization 59

Pharmacy Is Right For Me

AUGUST 10, 2022

I joined the Janssen Pharmaceutical Companies of Johnson & Johnson in 2007 as a Medical Science Liaison from the Rainbow Center for Women, Children, and Families in Jacksonville, Florida, where I served as an HIV Clinical Specialist and Clinical Assistant Professor at the University of Florida School of Pharmacy.

Vaccines 130

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 130

Outsourcing Pharma

MAY 17, 2022

The agency has removed the hold placed on the pharmaceutical companyâs IND for injectable lenacapavir, which is intended for HIV treatment and prevention.

52

52

European Pharmaceutical Review

FEBRUARY 23, 2023

Two newer simplified treatment options are at least as effective as standard of care in achieving viral suppression, according to results from a world-first international study into second-line human immunodeficiency virus (HIV) therapy. D2EFT enrolled 831 patients from 14 countries. Patients were randomised to one of the three arms.

97

97

ALiEM - Pharm Pearls

MARCH 11, 2024

In July 2022, a 32-year-old male with a past medical history of HIV (on antiretroviral therapy, CD4 390, viral load undetectable) presented to the emergency department with constitutional symptoms and a rash for 4-5 days. View other cases from this Clinical Image Series on ALiEM. Laboratory Data Complete Blood Count (CBC) : WBC: 19.5

Hospitals 140

Hospitals Documentation 140

Pharmaceutical Technology

AUGUST 23, 2022

Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. A long-acting HIV capsid inhibitor, lenacapavir has a multi-stage mechanism of action. A decision on the approval is anticipated by 27 December.

119

119

Pharmacy Times

JUNE 1, 2023

The primary medication therapies that can help with prophylaxis against HIV include pre-exposure prophylaxis and non-occupational post-exposure prophylaxis.

49

49

European Pharmaceutical Review

NOVEMBER 17, 2022

An innovative ingestible sensor technology tested in an interventional clinical trial provided HIV patients with real-time antiretroviral dosage data , enabling them to better control their infection. The study is one of earliest that uses an FDA-approved ingestible sensor system for ARV therapy in HIV-infected adults.

Dosage 93

Dosage 93

Pharmacy Times

JANUARY 3, 2024

Pharmacists involvement in HIV care and treatment has been shown to lead to clinically and statistically significant improvements in ART adherence, as well as greater viral load suppression for patients with HIV.

49

49

European Pharmaceutical Review

NOVEMBER 30, 2022

The European Commission (EC) has granted the first paediatric marketing authorisation for Gilead’s new low-dose tablet Biktarvy ® (bictegravir 30mg/emtricitabine 120mg/tenofovir alafenamide 15mg) in the European Union (EU) to treat human immunodeficiency virus (HIV). A milestone in the journey to overcoming HIV.

Adverse Reactions 91

Adverse Reactions Labelling Dosage 91

European Pharmaceutical Review

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has approved Gilead’s Sunlenca (lenacapavir), a capsid inhibitor for adults living with human immunodeficiency virus type 1 (HIV-1), who cannot be successfully treated with other available treatments. After 52 weeks, 83 percent of participants continued to have HIV RNA suppression.

Adverse Reactions 88

Adverse Reactions Labelling 88

Express Pharma

OCTOBER 9, 2023

A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. The researchers observed that, in the presence of these molecules, HIV replication does not occur.

Packaging 111

Packaging Communication Drug Development 111

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunity Immunization 117

European Pharmaceutical Review

AUGUST 25, 2022

The European Commission (EC) has granted marketing authorisation to a new, twice yearly treatment option for people whose HIV no longer effectively responds to their current therapy. Lenacapavir provides an innovative long-acting HIV therapy option with the potential to transform the clinical landscape.”.

Hospitals 84

Hospitals Drug Development 84

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. The product will be given to HIV patients whose previous HBV vaccination failed to prevent against the virus.

Vaccines 81

Vaccines Immunity Immunization 81

Pharmacy Times

DECEMBER 18, 2023

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

57

57

Pharmaceutical Technology

FEBRUARY 19, 2024

S-365598 is under clinical development by ViiV Healthcare and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

40

40

The Guardian - Pharmaceutical Industry

SEPTEMBER 28, 2023

GSK-controlled company works on developing patient-administered treatment by end of the decade One of the world’s largest commercial developers of HIV drugs is working on a treatment that can be injected by patients at home every two to three months by the end of the decade, saving them frequent visits to the clinic.

55

55

Express Pharma

AUGUST 13, 2023

A study published in the journal Nature Communications has identified a new pathway that human immunodeficiency virus (HIV) uses to enter the nucleus of a healthy cell, where it can then replicate and go on to invade other cells. The researchers observed that, in the presence of these molecules, HIV replication does not occur.

Packaging 98

Packaging Communication Drug Development 98

Pharmafile

MARCH 13, 2023

Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies in relation to fraudulent claims for HIV medications. read more

52

52

European Pharmaceutical Review

MAY 16, 2023

1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs). in a 2023 paper published in the Journal of Clinical Microbiology. To facilitate this, regulation of cell therapies has transformed at pace in recent decades.

Hospitals 91

Hospitals 91

Pharmaceutical Technology

DECEMBER 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection. A long-acting HIV capsid inhibitor, Sunlenca is intended for dosing twice a year.

59

59

Outsourcing Pharma

SEPTEMBER 1, 2021

Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection.

Vaccines 64

Vaccines 64

pharmaphorum

DECEMBER 2, 2022

New research from ViiV Healthcare has revealed a widespread gap in public knowledge and understanding of HIV worldwide, with three-quarters of people reporting that there are still negative perceptions of people living with HIV. Person-first language must be the absolute norm to help challenge HIV-related stigma and discrimination.

52

52

Pharmaceutical Technology

DECEMBER 20, 2023

LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

Immunity 40

Immunity Immunization 40

pharmaphorum

FEBRUARY 9, 2021

The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART). . The post ViiV’s Rukobia cleared in EU as rescue HIV therapy appeared first on.

98

98

Pharmacy Times

DECEMBER 6, 2022

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.

49

49

Pharmaceutical Technology

SEPTEMBER 14, 2023

(Islatravir + ulonivirine) is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

52

52

Pharmafile

JANUARY 19, 2023

Johnson & Johnson (J&J) has announced that it has ended its clinical trial for its experimental HIV vaccine, following disappointing results showing that the jab was ineffective at preventing HIV infections. read more

Vaccines 40

Vaccines Communication 40